When will Upadacitinib be included in medical insurance?

Upadacitinib (Upadacitinib) is a novel Janus kinase (JAK) inhibitor and a relatively new drug used to treat autoimmune diseases. has emerged as a promising drug candidate for the treatment of inflammatory diseases, including Crohn's disease. The JAK kinase family plays a key role in mediating signaling pathways downstream of various cytokine receptors involved in the regulation of immune responses.

The original drug upadatinib has been marketed in China and has entered the scope of Class B medical insurance through the relevant regulations of the National Medical Insurance Bureau, but only patients who meet the indications can be reimbursed, and the indications may include12 years old and above Second-line treatment for the above patients with refractory, moderate to severe atopic dermatitis; second-line treatment for adult patients with active psoriatic arthritis, and second-line treatment for adult patients with moderate to severe active rheumatoid arthritis. For specific relevant information, please consult the local medical insurance bureau or hospital. However, patients with known allergy to upadacitinib or any of its excipients are prohibited from using upadacitinib.

Upadatinib's original brand drug , which is marketed in China and has entered the national medical insurance, is sold as upadatinib sustained-release tablets. The price of each box of 15mg*28 tablets may be around RMB 3,000. The European version of the original drug sold overseas is priced at more than 20,000 yuan for 15mg*30 tablets (the price may fluctuate due to exchange rates), which is expensive. Cheaper upadatinib generic drugs are also sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 15mg*30 tablets produced by Bangladesh pharmaceutical factory is around 900 yuan (the price may fluctuate due to the exchange rate).